AQST - Aquestive Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

AQST is currently covered by 6 analysts with an average price target of $7.81. This is a potential upside of $4.98 (175.97%) from yesterday's end of day stock price of $2.83.

Aquestive Therapeutics's activity chart (see below) currently has 45 price targets and 75 ratings on display. The stock rating distribution of AQST is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 18.9% with an average time for these price targets to be met of 81.63 days.

Highest price target for AQST is $10, Lowest price target is $9, average price target is $9.5.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 02-Apr-2025. First documented stock forecast 20-Aug-2018.

Currently out of the existing stock ratings of AQST, 37 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$7 (233.33%)

$10

1 months 3 days ago
(02-Apr-2025)

8/28 (28.57%)

$6.96 (228.95%)

290

Buy

$10

$7 (233.33%)

$7

5 months 29 days ago
(06-Nov-2024)

1/7 (14.29%)

$4.93 (97.24%)

52

Buy

$9

$6 (200.00%)

$9

6 months 27 days ago
(08-Oct-2024)

0/10 (0%)

$4.08 (82.93%)

Buy

$7

$4 (133.33%)

$10

1 years 1 months 7 days ago
(28-Mar-2024)

0/8 (0%)

$2.74 (64.32%)

Buy

$12

$9 (300.00%)

$10

1 years 1 months 20 days ago
(15-Mar-2024)

0/2 (0%)

$5.91 (97.04%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AQST (Aquestive Therapeutics) average time for price targets to be met?

On average it took 81.63 days on average for the stock forecasts to be realized with a an average price target met ratio 18.9

Which analyst has the current highest performing score on AQST (Aquestive Therapeutics) with a proven track record?

RAGHURAM SELVARAJU

Which analyst has the current lower performing score on AQST (Aquestive Therapeutics) with a proven track record?

FRANCOIS BRISEBOIS

Which analyst has the most public recommendations on AQST (Aquestive Therapeutics)?

Raghuram Selvaraju has 3 price targets and 17 ratings on AQST

Which analyst is the currently most bullish on AQST (Aquestive Therapeutics)?

Francois Brisebois with highest potential upside - $9

Which analyst is the currently most reserved on AQST (Aquestive Therapeutics)?

Gary Nachman with lowest potential downside - $4

Aquestive Therapeutics in the News

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?